Last reviewed · How we verify
NCT06160102
Appropriate Medication Use for Individuals With Intellectual Disabilities - A Matter of Life
NA trial testing Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities in Disabilities, Intellectual in 110 participants. Participants enrolled and being followed up; not accepting new ones.
31 July 2027
Quick facts
| Lead sponsor | Vestvagoy Municipality |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 110 |
| Start date | 15 August 2023 |
| Primary completion | 31 July 2027 |
| Estimated completion | 31 July 2027 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities
Conditions studied
- Disabilities, Intellectual — all drugs for Disabilities, Intellectual →
- Disability, Developmental — all drugs for Disability, Developmental →
Sponsor
Vestvagoy Municipality
Who can join
Adults 1 to 99, any sex, with Disabilities, Intellectual or Disability, Developmental. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The innovation idea is to develop valuable new knowledge about safe drug use in people with intellectual and/or developmental disabilities (IDDs). The main goal is to design a framework (routines and processes) that ensures safe drug use and provides qualitatively better services for people with IDDs. Secondary goals are that employees will experience better security when working with medicines, and interact better with people with IDD and relatives by implementing digital support functions. The innovation idea is specifically to develop/improve the following: 1) Medication management: Coordinating routines, procedures and work processes regarding all aspects of drug use, medication handling, and communication between care units for people with IDDs. 2) Medication therapy: Chart review of prescribed medication and gather knowledge about challenges related to drug use in this group. Based on this, we will develop new methods for drug reconciliation and medication reviews to optimize drug use. 3) New framework for safe drug use in the community-based services for people with IDDs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06160102
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06160102 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vestvagoy Municipality
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06160102.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing